Carbidopa-d3 (monohydrate)

Carbidopa-d3 (monohydrate) is the deuterium labeled Carbidopa monohydrate. Carbidopa ((S) - (-) -Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth[1][2].

Product Specifications

CAS Number

[1276197-58-0]

Product Name Alternative

(S) - (-) -Carbidopa-d3 (monohydrate)

UNSPSC

12352005

Hazard Statement

H302-H319

Target

Aryl Hydrocarbon Receptor

Type

Isotope-Labeled Compounds

Related Pathways

Immunology/Inflammation

Field of Research

Cancer; Neurological Disease

Purity

98.0

Solubility

10 mM in DMSO

Smiles

OC(C([2H])=C1C[C@@](NN)(C)C(O)=O)=C(C([2H])=C1[2H])O.O

Molecular Formula

C10H13D3N2O5

Molecular Weight

247.26

Precautions

P264-P270-P280-P305+P351+P338-P330-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Gilbert JA, et al. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000;6 (11) :4365-4372.|[3]Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM) . Biochem J. 2017;474 (22) :3763-3765. Published 2017 Nov 6.|[4]Fermaglich J. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. Med Ann Dist Columbia. 1974;43 (12) :587-591.